Alentis Therapeutics’ Post

We've updated our MRD Ad Board! DeciBio conducted 10 interviews with biopharma executives and oncologists to explore how MRD utilization has changed over the past six months and dive deep on vendor-specific feedback. View our Q4 MRD Ad Board here: https://lnkd.in/eC_CYMPe #MRD #adboard #advisoryboard #biopharma #oncologists

If you have been following solid tumor MRD at all over the past few years, you know just how quickly the landscape is changing. The is a constant stream of new reimbursement decisions, product launches, and partnerships, all of which are driving how (and how much) biopharma and clinical stakeholders are utilizing the tools. We interviewed 10 oncologists and decision-makers in the biopharmaceutical industry to discuss trends in adoption over the last six months, considerations in evaluating vendors, and near-term expectations for utilization. The report is available on our website: https://lnkd.in/gXfhdTRZ. Please reach out if you would like to discuss! #MRD #precisionmedicine #liquidbiopsy Check out Natera, Guardant Health, Personalis, Inc., NeoGenomics Laboratories, Invitae, Foundation Medicine, and more

In this week's Weekly Watchlist, we focus on Phase 3 catalysts across indications for the next 6 months. Check out the link below! #phase3 #drugpipeline #fasterscience #biopharmcatalyst #fdacalendar #weeklywatchlist #biotech #biotechinvestor #biotechinvesting

BioPharmCatalyst's Weekly Watchlist for August 12th, 2024: Exciting updates ahead! MeiraGTX Holdings (NASDAQ: MGTX) and IO Biotech (NASDAQ: IOBT) are gearing up for significant milestones in the coming months. MeiraGTX Holdings is on track to unveil data from its Phase 3 trial of bota-vec, targeting improvements in retinal sensitivity and vision for XLRP patients by 3Q 2024. Meanwhile, IO Biotech's top candidate, IO102-IO103 in conjunction with Keytruda, targets melanoma and is poised for an overall response rate readout during the same period. Stay informed on these and other key phase 3 catalysts set for the quarter by visiting the article below. Don't miss out! Subscribe to our Weekly Watchlist via the website link provided. https://lnkd.in/eSsUi3C2 #biotech #biotechstocks #weeklywatchlist #fdacalendar #fasterscience #catalysts #pharma #biotechinvesting #oncology #drugpipeline

@Catailyst Trending Topics Incyte to Present Late-Breaking Phase 3 Results for #Retifanlimab (Zynyz®) and Initial Data from Phase 1 #CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024 https://lnkd.in/e-dTVEhQ Versant Ventures and Novartis Launch Borealis Biosciences, Inc. With $150 Million in Funding https://lnkd.in/eXP8bb29 Bayer Initiates #Phase II Study of Soluble Guanylate Cyclase Activator (BAY3283142) in Patients With #Chronic #Kidney #Disease https://lnkd.in/eXVVr_43 Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 #Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat #Pain https://lnkd.in/eg2_Rvkp

Last day of #BIOEuropeSpring by EBD Group in Barcelona, but not last chance to engage with peers in drug discovery and pharmaceuticals. At Indivumed Therapeutics we strive to bring novel therapies to treat #cancer patients. Collaborations and partnerships are crucial to advance together to bring #targetdiscovery programs to the clinical stage. Stay tuned! #clinicalresearch #beyondgenomics #proteomics #phosphoproteomics #data #multiomics #mathematics #bioinformatics

Excited to enhance my skills and knowledge on 'SiRNAs: A New Era in Cancer Chemoprevention, organized by the Society of Pharmaceutical Sciences and Research (SPSR) on the occasion of World Cancer Day, February 4, 2024.! Ready to engage, learn, and network with industry experts. #ProfessionalDevelopment #WebinarParticipation"

#AACR24 Analysis 3: Kelonia Therapeutics and Carisma Therapeutics presented preclinical updates from their programs using innovative #celltherapy platforms. Celltelligence provides insights and key context for selected presentations. The following topics are covered: • Kelonia reported preclinical data from its KLN-1010, an in vivo iGPS-induced CAR-T for MM treatment • Carisma shared its new myeloid cell-based platform, referred to as Engineered Microenvironment Converters (EM-C), for solid tumors Celltelligence provides insights: https://bit.ly/CT-867710

Here's to one more valuable participation certificate on "translational phytomedicine for cancer : Bridging laboratory and clinical application" by @Dr.Lekshmi R. nath thankful for Society of Pharmaceutical Sciences and Research (SPSR) for insightful session. #oncology #phytomedicine #livercancer #kemapride #uttrosideB #cervicalcancer

𝐀𝐛𝐛𝐕𝐢𝐞 𝐩𝐚𝐲𝐬 $𝟏𝟎𝐁 𝐭𝐨 𝐚𝐜𝐪𝐮𝐢𝐫𝐞 𝐈𝐦𝐦𝐮𝐧𝐨𝐆𝐞𝐧, 𝐛𝐲 𝐝𝐨𝐮𝐛𝐥𝐢𝐧𝐠 𝐝𝐨𝐰𝐧 𝐨𝐧 𝐫𝐞𝐝-𝐡𝐨𝐭 𝐀𝐃𝐂 (𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐝𝐫𝐮𝐠 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞) 𝐜𝐚𝐧𝐜𝐞𝐫 𝐟𝐢𝐞𝐥𝐝 In November 2023, AbbVie is shelling out $10.1 #billion in #cash to acquire maker of #ovariancancertreatment Elahere by ImmunoGen, Inc., which has won approval form FDA (Food and Drug Administration). This acquisition has allowed AbbVie’s entry into solid #tumorspace and thus, strengthen its position in #oncology pipeline. ➤𝐎𝐭𝐡𝐞𝐫 𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐫𝐞𝐩𝐨𝐫𝐭:https://bit.ly/3RnYlVW #antibodydrugconjugates #abbvie #Immunogen #prophecy #marketresearch #prophecymarketinsights